PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 5, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that
David Stack, president and chief executive officer of Pacira
Pharmaceuticals, will close The NASDAQ Stock Market on Monday, April 8,
2013, in celebration of the one-year anniversary of the commercial
launch of EXPAREL® (bupivacaine liposome injectable suspension). Members
of the Pacira team will join Mr. Stack at the ceremony at the NASDAQ
MarketSite in Times Square in New York City.
“We are honored to preside over The NASDAQ Stock Market Closing Bell to
mark the one-year anniversary of the commercial launch of EXPAREL® and
its successful market traction in that first year,” said Mr. Stack. “We
continue to see tremendous growth in new customers and expansion in
hospitals that have gained experience with the product, supporting our
belief that EXPAREL provides a significant opportunity to improve
patient care as well as hospital economics and provide a new treatment
for postsurgical pain.”
The ceremony will be broadcast live beginning at 3:50 p.m. ET and can be
accessed at: http://www.nasdaq.com/about/marketsitetowervideo.asx.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company's current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable
suspension), was commercially launched in the United States in April
2012. EXPAREL and two other products have utilized the Pacira
proprietary product delivery technology DepoFoam®, a unique
platform that encapsulates drugs without altering their molecular
structure and then releases them over a desired period of time.
Additional information about Pacira is available at www.pacira.com.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
Chief
Financial Officer
